live webinar

Psychedelic Therapy: Problems and Promises

On

Featuring:

Robin Carhart-Harris, PhD
and
Greg Fonzo, PhD
and
Stephen Ross, MD
and
Rachel Yehuda, PhD
and
Professional
Fall Forum 2022 - Psychedelic Therapy: Problems and Promises
Thursday, October 27, 2022 12:00 pm
- 2:00 pm ET
Category
PTSD
Pharmacology
Depression
Alternative Therapies
Anxiety Disorders
Treatment
CE/CME Credit
2.00

Member Prices

30.00

Non-Member Prices

45.00

The past several years have witnessed a resurgence of interest in classic psychedelics (e.g., psilocybin, LSD, DMT) and empathogens/entactogens (e.g., MDMA) for their potential therapeutic applications in a range of psychiatric conditions, including major depressive disorder, treatment-resistant depression, PTSD, and substance use disorders. Although psilocybin and MDMA are now in late-stage FDA regulatory clinical trials, there is still a paucity of adequately powered, randomized, controlled data on the efficacy, tolerability and safety of these approaches. Major unresolved issues include the role of “set and setting” and non-drug factors in the potential benefit of these approaches, and the optimal delivery of psychedelic-assisted psychotherapy for patients. This webinar brings together several leading experts to provide their clinical and research perspectives on the psychedelic medicine field as it pertains to depression, anxiety, and PTSD.

A leading academic psychiatry expert (Dr. Carhart-Harris) will serve as keynote speaker and discuss the state of the science for psilocybin in depression, including a discussion of its history, neuropsychopharmacology, clinical effects, and safety.

This keynote lecture will be followed by a panel discussion including leading clinical and research faculty experts in classic psychedelics and MDMA (Drs. Fonzo, Yehuda, and Ross) who will discuss emerging scientific, clinical, and regulatory challenges for the field.

Attendees of this interactive webinar will have the opportunity to engage with the faculty and will gain a better understanding of the complex problems and potential opportunities that psychedelics pose for clinical practice.

Learning Objectives:

  1. To describe the neuropsychopharmacology and mechanisms of actions of several classic psychedelics and empathogens
  2. To review the strengths and limitations of recent clinical trials of psilocybin and MDMA for patients with treatment-resistant depression and PTSD, respectively
  3. To discuss challenges for clinicians in the adoption and implementation of psychedelic-assisted psychotherapy
     

Keynote Presentation | Psychedelics: Brain Mechanisms

Presented by Robin Carhart-Harris, PhD

This talk will take a multi-level view of the brain action of classic psychedelic drugs, i.e., drugs that share the property of activating the serotonin 2A receptor. Beginning at the receptor level, it moves through a developmental and evolutionary understanding of serotonergic functioning and brain plasticity, placing emphasis on the context dependency of responses to classic psychedelic compounds. It will review the dynamic, whole-brain action of psychedelics and how this relates to knowledge of the development and evolution of global brain function and anatomy. It couches our understanding of the therapeutic action of psychedelic therapy within a predictive coding framework and reviews recent trial and imaging results from a double-blind randomized controlled trial of psilocybin therapy vs escitalopram for depression. 

Panel Discussion | Psychedelic Therapy: Problems and Promises

Expert Panelists: Greg Fonzo, PhD, Stephen Ross, MD, and Rachel Yehuda, PhD

The panel discussion will bring together several clinical and research faculty experts in classic psychedelics and MDMA (Drs. Fonzo, Yehuda, and Ross) to discuss emerging scientific, clinical, and regulatory challenges for the field. Attendees of this interactive webinar will have the opportunity to engage with the faculty and will gain a better understanding of the complex problems and potential opportunities that psychedelics pose for clinical practice.


Discounted rates available for students, professional in developing countries, and members of the media.

Presenter(s) Biography

Robin Carhart-Harris, PhD

Robin Carhart-Harris, PhD

Robin Carhart-Harris, PhD is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry and Director Neuroscape’s Psychedelics Division at the University of California, San Francisco. He moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, and clinical trials of psilocybin therapy for severe mental illnesses. He has authored over 130 papers, with over forteen thousand citations. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, and in 2021, was named in TIME magazine’s ‘100 Next’ – a list of 100 rising stars shaping the future.  

and

Greg Fonzo, PhD

Gregory Fonzo, PhD

Greg Fonzo, PhD, is an Assistant Professor in the Department of Psychiatry at Dell Medical School with a courtesy appointment in the Department of Psychology.  He graduated summa cum laude from the University of Georgia Honors Program in 2005 with a dual bachelor’s degree in biology and psychology. He received his doctorate in clinical psychology in 2013 from the San Diego State University/University of California-San Diego Joint Doctoral Program. He completed his postdoctoral research fellowship at the Stanford University School of Medicine and the Sierra-Pacific Mental Illness Research, Education and Clinical Center (MIRECC) at the Palo Alto Veterans Affairs Healthcare System.  Dr. Fonzo’s research focuses on elucidating neurobiological mechanisms underlying manifestation and treatment of affective and stress-related disorders  and designing novel neuroscience-informed treatment modalities using tools such as neuroimaging and neuromodulation.  He is currently leading efforts at The University of Texas at Austin to understand how psychedelic-assisted psychotherapy augments neural and psychological function to alleviate mental illness and how to improve and enhance the prediction, durability, and magnitude of therapeutic benefits.
 

and

Stephen Ross, MD

Stephen Ross, MD

Dr. Stephen Ross is Research Associate Professor of Psychiatry and Child & Adolescent Psychiatry at the NYU Grossman School of Medicine. Dr. Ross is a founding member of the NYU Psychedelic Research Group and is currently associate director of the NYU Langone Health (NYULH) Center for Psychedelic Medicine and director of the NYULH Psychedelic Medicine Research Training Program. In 21 years at NYU and Bellevue, Dr Ross has been involved in a variety of leadership roles in administration, teaching and research. He previously served as Director of the Division of Alcoholism and Drug Abuse in the Psychiatry Department at Bellevue Hospital Center for 12 years, Director of Addiction Psychiatry at NYULH/Tisch Hospital, Director of the NYU Addiction Psychiatry Fellowship, Director of the Bellevue Inpatient Dual Diagnosis Training Unit, and Director of the Bellevue Opioid Overdose Prevention Program. Dr Ross’s main research interests focus on developing novel pharmacologic-psychosocial approaches to treating: addictive disorders, including the intersection between pain and addiction; psychiatric and existential distress associated with advanced or terminal cancer; major depression; PTSD; and personality disorders. Dr Ross  is principal investigator or co-principal investigator on several ongoing and completed psychedelic-focused studies at NYULH including: phase II RCT of psilocybin-assisted psychotherapy in patients with life-threatening cancer-related psychiatric and existential distress, phase I/II RCT of LSD-assisted psychotherapy in advanced cancer pain syndromes, phase II RCT of psilocybin-assisted psychotherapy in alcohol use disorder, phase I/II controlled trial administering psilocybin to religious professionals, and phase II RCT of psilocybin treatment for Major Depressive Disorder. Dr Ross also acts as a co-investigator and study therapist for phase II/III trials of MDMA-assisted psychotherapy for PTSD, and is an expert in cannabinoid therapeutics and PI of a NIDA funded study of CBD administration in patients with chronic radicular pain on chronic opioid therapy.  

and

Rachel Yehuda, PhD

Rachel Yehuda, PhD

Rachel Yehuda, PhD, is an Endowed Professor of Psychiatry and Neuroscience of Trauma.  She is also Director of Mental Health at the James J. Peters Veterans Affairs Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress studies having authored more than 500 academic papers, chapters, and books in the field of PTSD and intergenerational trauma.  Dr. Yehuda's research on cortisol and epigenetic mechanisms has revolutionized our understanding of the neurobiology and treatment of PTSD.  In 2019, Dr. Yehuda was elected to the National Academy of Medicine for her seminal contributions to understanding the psychological and biological impact of traumatic stress.  Last year, Dr. Yehuda established and now directs the Center for Psychedelic Psychotherapy and Trauma Research, and has been named one of the most influential women in the psychedelic field.

and
Professional Post
On
CE/CME Accreditation Statement

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.